Compare USPH & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USPH | NEO |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2008 |
| Metric | USPH | NEO |
|---|---|---|
| Price | $72.40 | $8.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $101.67 | $11.14 |
| AVG Volume (30 Days) | 122.9K | ★ 1.6M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $780,990,000.00 | N/A |
| Revenue This Year | $10.62 | $10.63 |
| Revenue Next Year | $6.30 | $9.73 |
| P/E Ratio | $51.70 | ★ N/A |
| Revenue Growth | ★ 16.33 | N/A |
| 52 Week Low | $66.67 | $4.72 |
| 52 Week High | $93.50 | $13.74 |
| Indicator | USPH | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 55.49 |
| Support Level | $71.99 | $7.33 |
| Resistance Level | $76.84 | $8.84 |
| Average True Range (ATR) | 2.56 | 0.48 |
| MACD | -0.26 | 0.11 |
| Stochastic Oscillator | 7.12 | 89.47 |
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.